Lonza Group AG stock (CH0013841017): CDMO giant upgrades 2025 growth target after strong first half

Lonza Group AG is back in growth mode. The Swiss contract development and manufacturing specialist reported a sharp rebound in business in the first half of 2025 and upgraded its medium?term outlook for its key CDMO activities, while continuing to pour capital into biologics and bioconjugation sites that serve many US and global pharma customers, according to company disclosures and market data published in 2025 and 2026.Stockanalysis.com as of 05/19/2026Lonza investor information as of 02/07/2025

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

Lonza Group AG: core business model

Lonza Group AG is one of the world’s largest contract development and manufacturing organizations, providing services across the pharmaceutical value chain from early?stage development to large?scale commercial production. The group focuses on biologics, small molecules, cell and gene therapies and bioscience solutions used in research and diagnostics for global clients including large US drugmakers.Lonza corporate profile as of 05/10/2026

As a pure?play CDMO following the separation of its specialty ingredients activities, Lonza aims to generate stable, long?term revenue through multi?year manufacturing and development contracts. The company typically works behind the scenes, producing active ingredients and finished dosage forms on behalf of pharmaceutical and biotech customers rather than selling its own branded medicines, which shapes its risk and return profile.

The business is organized into biologics, small molecules, cell and gene technologies and a bioscience platform. Biologics is the largest contributor, reflecting a broader industry shift from traditional small?molecule pills toward complex injectable biologic therapies for oncology, immunology and rare diseases. This mix exposes Lonza to structural growth in biologics, while also requiring high capital intensity and strict quality standards.

Lonza’s core pitch to customers is its ability to provide scale, regulatory know?how and advanced technologies that many smaller biotech firms, and even some larger pharma companies, find hard to maintain in?house. The company operates a global network of plants in Europe, North America and Asia, including important manufacturing hubs in Visp in Switzerland and in the United States, which are relevant for US?based pharma and biotech sponsors seeking supply security near their home market.

Main revenue and product drivers for Lonza Group AG

Biologics manufacturing is the main revenue engine for Lonza. This segment covers mammalian and microbial manufacturing of monoclonal antibodies and other complex proteins, often under long?term supply agreements. The company reported that biologics and related CDMO services drove a majority of its CHF 3.6 billion in sales in the first half of 2025, with constant?currency growth of about 19% and an EBITDA margin of 29.6%, according to its half?year report published in July 2025.Lonza HY 2025 report as of 07/24/2025

Small?molecule contract manufacturing remains another key driver, providing services for oral and injectable drugs that are still widely used in cardiovascular disease, neurology and other chronic conditions. While the growth profile of small molecules is more moderate compared with biologics, Lonza benefits from a broad customer base and the ability to offer complex chemistries and highly potent active ingredients that command premium pricing and require specialized facilities.

The cell and gene technologies segment, though smaller in absolute revenue terms, is strategically important. It supplies viral vectors and related services used in cell and gene therapies, an area of high scientific and commercial interest in oncology and rare genetic disorders. Lonza has indicated in recent updates that it sees continued demand from US and European biotechs in this field, though the pace of approvals and funding cycles can lead to fluctuations in order patterns over shorter time frames.

Beyond manufacturing, the bioscience division sells media, reagents and tools used in discovery and development laboratories. This business benefits from broader growth in biologics research and cell culture applications worldwide. Market analysts expect the global cell culture media market to nearly double from around USD 3.7 billion in 2026 to roughly USD 7.1 billion by 2036, driven by expanding biologics and cell therapy pipelines, according to a study released by Future Market Insights on May 19, 2026.PR Newswire / Future Market Insights as of 05/19/2026

Recent growth upgrade and capacity investments

Following a period of slower growth and restructuring, Lonza reported that its sales reached approximately CHF 3.6 billion for the first half of 2025, an increase of about 19% at constant exchange rates versus the prior?year period. The company also disclosed an EBITDA margin of 29.6% for the same period in its July 2025 half?year results release, signaling improved operational leverage as volumes recovered.Lonza investor news as of 07/24/2025

Building on this momentum, Lonza raised its outlook for CDMO sales growth in 2025. In its communications around the half?year results, the company indicated that it now expected CDMO sales to increase by roughly 20% to 21% for the full year 2025 at constant exchange rates. This represented an upgrade from a previously more cautious stance and underscored management’s confidence in the underlying demand, particularly in biologics and certain advanced therapy platforms.

At the same time, Lonza continues to invest in expanding capacity. The company has announced multiple projects at its flagship Visp site in Switzerland, including additional bioconjugation infrastructure and multipurpose manufacturing suites. A 2026 industry update on the oligonucleotide CDMO market noted that Lonza had committed further capital to bioconjugation capabilities at Visp, reflecting the growing importance of antibody?drug conjugates and other complex modalities in oncology and specialty therapies.PharmiWeb market report as of 05/19/2026

These investments are intended to align Lonza’s manufacturing footprint with evolving client needs and to support projects that may serve large patient populations if clinical trials are successful. However, they also mean that the company faces high capital expenditures and must carefully manage utilization rates and contract visibility to maintain its profitability targets over the medium term.

Strategic partnerships and relevance for US pharma

Lonza’s role as a strategic partner to major pharmaceutical groups is illustrated by a number of announced collaborations. For example, Bristol Myers Squibb and Lonza disclosed a licensing and manufacturing agreement aimed at strengthening Bristol Myers’ oncology pipeline, under which Lonza provides CDMO services for selected assets, according to a joint announcement discussed in industry media in early 2026.CHEManager report as of 03/11/2026

Such partnerships underscore the company’s relevance for US drug developers looking to secure high?quality manufacturing capacity in biologics and complex modalities. Lonza operates facilities in North America and collaborates closely with US?based teams on process development, scale?up and commercial supply. For investors following US pharma and biotech names, Lonza can therefore be seen as an indirect way to gain exposure to the broader pipeline of biologics and cell and gene therapies being advanced by these firms.

From a portfolio perspective, Lonza’s revenue base is geographically diversified, with the United States representing an important end market through both domestic production and exports from European plants. Currency movements and US regulatory expectations, including FDA inspections of key sites, can therefore play a role in the company’s risk profile, which investors tracking cross?border healthcare suppliers often take into account.

Conclusion

Lonza Group AG has moved from a period of adjustment back toward growth, with its half?year 2025 results showing double?digit constant?currency sales expansion and healthy margins, and its upgraded 2025 CDMO growth target of around 20% to 21% reflecting confidence in demand. At the same time, heavy investment in biologics, bioconjugation and advanced therapies infrastructure, including at the Visp site, underpins future capacity but increases capital and execution risk. For US?focused investors watching global healthcare supply chains, Lonza offers insight into how a leading CDMO is positioning itself at the intersection of biologics, cell and gene therapies and large pharma outsourcing trends without representing a direct bet on any single drug candidate.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.